Currently, one in six platelet transfusions are ineffective and patients who receive three consecutive, ineffective platelet transfusions could die. New Ventures BC 2009 Finalist LightIntegra Technology Inc. is developing a technology to save the lives of cancer, heart surgery and bleeding patients through fast access to platelet and microparticle profiles in blood.
LightIntegra’s ThromboLUX, developed by a Canadian Blood Services scientist, uses dynamic light-scattering technology to test the platelets prior to using them in blood transfusions to prevent and stop bleeding. LightIntegra’s technology measures the entire spectrum of particles in blood plasma that tells the story of the donor’s health or the quality of platelet or plasma products for transfusion.